With the use of the Coxsackie adenovirus receptor at high tumor expression levels in clinical trials related to SCLC treatment recently, a recombinant Coxsackie virus B3 (CVB3) has been exploited to develop a recombinant Coxsackie virus B3, which has potent antiviral efficacy for TP53/RB1 mutant SCLC while minimizing the toxicity to normal tissues. Here, RB1 is linked to small cell lung carcinoma.